ArticleSurgical case reports2025
Mitral Valve Repair for Mitral Regurgitation Associated with Antiphospholipid Syndrome: A Case Report.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntiphospholipid syndrome (APS) is a multisystem autoimmune disorder of hypercoagulability, characterized by arterial and venous thrombosis, recurrent fetal losses, thrombocytopenia, and circulating antiphospholipid antibodies. Among valvular manifestations associated with APS, mitral regurgitation (MR) is the most common, followed by aortic regurgitation. Surgical interventions for APS-related valvular diseases carry high perioperative morbidity and mortality. There are no established guidelines regarding the surgical management of APS-related MR. CASE PRESENTATION: A 46-year-old man underwent mitral valve repair for severe MR. Histopathological examination of the vegetation on the mitral valve revealed nonbacterial thrombotic endocarditis, and in combination with laboratory findings, the MR was diagnosed as associated with APS. Leaflet thickening and fusion progressed postoperatively, leading to moderate-to-severe MR and mitral stenosis within 2 years.
conclusionsIn cases where MR is the initial presentation of APS, preoperative diagnosis of APS can be challenging. Detailed, frame-by-frame transesophageal echocardiographic evaluation may aid in the preoperative identification of subtle valvular abnormalities suggestive of APS. When thrombocytopenia and a prolonged activated partial thromboplastin time (APTT) are identified during preoperative evaluation for valvular heart disease, tests for lupus anticoagulant, anticardiolipin antibody, and anti-β2 glycoprotein I antibody should be performed, and consultation with hematologists is recommended. Valve repair for MR associated with APS, which preserves valvular tissue that may become diseased in the future, is likely to result in poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.